Roa P, Foglizzo V, Harada G, Repetto M, et al. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. Br J Cancer 2024;131:601-610.
PMID: 38902532